Home › NDC Lookup › RxCUI directory › RxCUI 2680138

Alpelisib 50 MG Oral Granules [Vijoice] — RxCUI 2680138

RxNorm drug concept · Semantic branded drug
RxCUI 2680138 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 7 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2680138
Official nameAlpelisib 50 MG Oral Granules [Vijoice]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asVijoice 50 MG Oral Granules
FDA products mapped4
Package NDCs mapped7
Reported Medicaid activity (SDUD)1,266 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alpelisib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • They treat different conditions, even though they contain the same active ingredient. Piqray is for adults with a specific type of advanced breast cancer — one that is hormone rece...
  • What exactly is alpelisib treating — is it the same condition for Piqray and Vijoice?
  • Yes, you should always take alpelisib with food — this meaningfully increases how much of the drug your body absorbs. The good news is that clinical data show no significant differ...
  • Do I have to take this with food, and does it matter what kind of food?
📖 Read our full Alpelisib guide →

🕸️ Concept Web — How Alpelisib 50 MG Oral Granules [Vijoice] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Alpelisib 50 MG Oral Granules [Vijoice] RxCUI 2680138

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Alpelisib 2169285
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Vijoice 2598454
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Alpelisib Oral Granules 2680134
    • Alpelisib Granule Product 2680133
    • Alpelisib Oral Product 2169297
    • Alpelisib Oral Granules [Vijoice] 2680137
    • Vijoice Granule Product 2680136
    • Vijoice Oral Product 2598456
    • Oral Granules 317690
    • Granule Product 1294708
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 2

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

4 products · 7 package NDCs
7 package NDCs map to RxCUI 2680138 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00078-1021-84 1 BLISTER PACK in 1 CARTON (0078-1021-84) / 28 TABLET in 1... VIJOICE Novartis Pharmaceuticals Corporation 2022-04-05
00078-1021-91 1 BLISTER PACK in 1 CARTON (0078-1021-91) / 28 TABLET in 1... VIJOICE Novartis Pharmaceuticals Corporation 2022-04-05
00078-1028-84 1 BLISTER PACK in 1 CARTON (0078-1028-84) / 28 TABLET in 1... VIJOICE Novartis Pharmaceuticals Corporation 2022-04-05
00078-1028-91 1 BLISTER PACK in 1 CARTON (0078-1028-91) / 28 TABLET in 1... VIJOICE Novartis Pharmaceuticals Corporation 2022-04-05
00078-1035-02 2 BLISTER PACK in 1 CARTON (0078-1035-02) / 1 KIT in 1 BLIS... VIJOICE Novartis Pharmaceuticals Corporation 2022-04-05
00078-1035-92 2 BLISTER PACK in 1 CARTON (0078-1035-92) / 1 KIT in 1 BLIS... VIJOICE Novartis Pharmaceuticals Corporation 2022-04-05
00078-1175-51 28 PACKET in 1 CARTON (0078-1175-51) / 1 GRANULE in 1 PACKE... VIJOICE Novartis Pharmaceuticals Corporation 2024-04-24
Observed labelers: Novartis Pharmaceuticals Corporation (7) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.